• 제목/요약/키워드: chemoradiation

검색결과 151건 처리시간 0.031초

자궁 경부암에서 방사선 단독치료와 방사선 및 화학요법 병행치료의 비교 (Comparison of the Result of Radiation Alone and Chemoradiation in Cervical Cancer)

  • 김재철;박인규
    • Radiation Oncology Journal
    • /
    • 제13권2호
    • /
    • pp.191-198
    • /
    • 1995
  • 목적: 자궁경부암의 치료에 있어 방사선 단독치료와 비교하여 방사선 및 화학요법 병행치료가 치료에 대한 반응, 생존율, 재발양상, 원격전이 및 부작용의 빈도 등에 영향를 주는가를 보고자 하였다. 방법: 경북대학교병원 치료방사선과에서 1985년 11월부터 1991년 12월까지 자궁경부암으로 근치적 방사선치료를 받은 135명의 환자를 대상으로 치료에 대한 반응, 생존율, 재발양상, 원격전이 및 부작용의 빈도에 대하여 후향적 분석을 하였다. 방사선 단독으로 치료한 환자는 56명이었고, cisplatin을 포함한 화학요법을 병행한 환자는 79명이었다. 대상 환자들의 추적조사기간은 5개월에서 105개월이었다(중간값: 47개월). FIGO 병기별 분류에 의하면, IB가 18명$(13.3\%),$ IIA가 7명 $(5.2\%),$ IIB가 97명 $(71.9\%),$ IIIB가 9명 $(6.7\%)E이었다. 결과: 방사선 단독치료군 중 51예 $(91.1\%),$ 병행치료군 중 68예 $(86.1\%)$에서 완전관해가 관찰되었다. 전체 환자의 5년생존율은 $73.3\%$였고, 병기별 5년생존율은 IB가 $88.9\%,$ IIA가 $85.7\%,$ IIB가 $73.8\%,$ IIIB가 $37.5\%$였다. 치료방법에 따른 5년생존율은 방사선 단독치료군에서 $81.9\%$였고, 병행치료군에서 $67.0\%$였다(p=0.22). 5년무병생존율은 방사선 단독치료군에서 $70.4\%$였고, 병행치료군에서 $68.5\%$였다 (p=0.85). 5년국소제어율은 방사선 단독치료군에서 $76.1\%$였고, 병행치료군에서 $73.8\%$였다(p=0.70). 5년원격제어율은 방사선 단독치료군에서 $83.9\%$였고, 병행치료군에서 $90.3\%$였다(p=0.59). 치료에 따른 골수억제는 방사선 단독치료군에서 3예 $(5.4\%),$ 병행치료관에서 14예 $(17.7\%)$가 관찰되었다(p<0.05). 내과적 치료로 호전되었던 방광염이 방사선 단독치료군에서 14예, 병행치료군에서 10예 관찰되었다. 내과적 치료로 호전되었던 직장염이 방사선 단독치료군에서 2예, 병행치료군에서 4예 관찰되었고, 외과적 치료를 요했던 직장천공이 병행치료군에서 1예 관찰되었다. 보존적 치료로 해결되었던 장폐쇄의 부작용은 방사선 단독치료군에서만 2예 관찰되었다. 양 군간의 방광염, 직장염, 소장폐쇄의 빈도에는 유의한 차이가 없었다. 결론: 방사선 단독치료군과 비교할 때 cisplatin을 포함한 화학요법의 병행은 치료에 대한 반응, 생존율, 재발양상, 원격전이에 영향을 미치지 않았고, 병행치료군에서 골수억제의 빈도가 더 높게 나타났다.

  • PDF

Prognostic Significance of 18F-fluorodeoxyglucose Positron Emission Tomography (PET)-based Parameters in Neoadjuvant Chemoradiation Treatment of Esophageal Carcinoma

  • Ma, Jin-Bo;Chen, Er-Cheng;Song, Yi-Peng;Liu, Peng;Jiang, Wei;Li, Ming-Huan;Yu, Jin-Ming
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권4호
    • /
    • pp.2477-2481
    • /
    • 2013
  • Aims and Background: The purpose of the research was to study the prognostic value of tumor 18F-FDG PET-based parameters in neoadjuvant chemoradiation for patients with squamous esophageal carcinoma. Methods: Sixty patients received chemoradiation therapy followed by esophagectomy and two 18FDG-PET examinations at pre- and post-radiation therapy. PET-based metabolic-response parameters were calculated based on histopathologic response. Linear regression correlation and Cox proportional hazards models were used to determine prognostic value of all PET-based parameters with reference to overall survival. Results: Sensitivity (88.2%) and specificity (86.5%) of a percentage decrease of SUVmax were better than other PET-based parameters for prediction of histopathologic response. Only percentage decrease of SUVmax and tumor length correlated with overall survival time (linear regression coefficient ${\beta}$: 0.704 and 0.684, P<0.05). The Cox proportional hazards model indicated higher hazard ratio (HR=0.897, P=0.002) with decrease of SUVmax compared with decrease of tumor size (HR=0.813, P=0.009). Conclusion: Decrease of SUVmax and tumor size are significant prognostic factors in chemoradiation of esophageal carcinoma.

Concurrent Chemoradiation with Weekly Cisplatin for the Treatment of Head and Neck Cancers: an Institutional Study on Acute Toxicity and Response to Treatment

  • Ghosh, Saptarshi;Rao, Pamidimukkala Brahmananda;Kumar, P Ravindra;Manam, Surendra
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권16호
    • /
    • pp.7331-7335
    • /
    • 2015
  • Background: Concurrent chemoradiation with three weekly high dose cisplatin is the non-surgical standard of care for the treatment of locally advanced head and neck cancers. Although this treatment regime is efficacious, it has high acute toxicity, which leads not only to increased treatment cost, but also to increased overall treatment time. Hence, the current study was undertaken to evaluate the acute toxicity and tumor response in head and neck cancer patients treated with concurrent chemoradiation using $40mg/m^2$ weekly cisplatin, which has been our institutional practice. Materials and Methods: This single institution retrospective study included data for 287 head and neck cancer patients treated with concurrent chemoradiation from 2012 to 2014. Results: The mean age of the patients was 48.8 years. The most common site of involvement was oral cavity. Most of the study patients presented with advanced stage disease. The mean overall treatment time was 56.9 days. Some 67.2% had overall complete response to treatment as documented till 90 days from the start of treatment. According to the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria, mucositis was seen in 95.1% of the patients. Dermatitis and emesis were observed in 81.9% and 98.6%, respectively. Regarding haematological toxicity, 48.8% and 29.6% suffered from anaemia and leukopenia, respectively, during treatment. Acute kidney injury was assessed using the Common Terminology Criteria for Adverse Events (CTCAE), and was found in 18.8% of the patients. Conclusions: Concurrent chemoradiotherapy with weekly cisplatin is an effective treatment regime for head and neck cancers with reasonable toxicity which can be used in developing countries, where cost of treatment is so important.

Variable uterine uptake of FDG in adenomyosis during concurrent chemoradiation therapy for cervical cancer

  • Yu, Jeong-Il;Huh, Seung-Jae;Kim, Young-Il;Kim, Tae-Joong;Park, Byung-Kwan
    • Radiation Oncology Journal
    • /
    • 제29권3호
    • /
    • pp.214-217
    • /
    • 2011
  • To avoid improper tumor volume contouring in radiation therapy (RT) and other invasive procedures, we report a case of uterine adenomyosis showing increased $^{18}F$-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET)/computed tomography (CT) mimicking malignant tumor in a 44-year-old woman during concurrent chemoradiation therapy (CCRT) for uterine cervical cancer. The adenomyosis was not associated with her menstrual cycle or with normal endometrium uptake, and it resolved one month after completion of RT. This case indicates that uterine adenomyosis in a premenopausal woman may show false positive uptake of $^{18}FDG$-PET/CT associated with CCRT.

Weekly Cisplatin-Based Concurrent Chemoradiotherapy for Treatment of Locally Advanced Head and Neck Cancer: a Single Institution Study

  • Ghosh, Saptarshi;Rao, Pamidimukkala Brahmananda;Kumar, P Ravindra;Manam, Surendra
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권16호
    • /
    • pp.7309-7313
    • /
    • 2015
  • Background: The organ preservation approach of choice for the treatment of locally advanced head and neck cancers is concurrent chemoradiation with three weekly high doses of cisplatin. Although this is an efficacious treatment policy, it has high acute systemic and mucosal toxicities, which lead to frequent treatment breaks and increased overall treatment time. Hence, the current study was undertaken to evaluate the efficacy of concurrent chemoradiation using 40 mg/m2 weekly cisplatin. Materials and Methods: This is a single institutional retrospective study including the data of 266 locally advanced head and neck cancer patients who were treated with concurrent chemoradiation using 40 mg/m2 weekly cisplatin from January 2012 to January 2014. A p-value of < 0.05 was taken to be significant statistically for all purposes in the study. Results: The mean age of the study patients was 48.8 years. Some 36.1% of the patients had oral cavity primary tumors. The mean overall treatment time was 57.2 days. With a mean follow up of 15.2 months for all study patients and 17.5 months for survivors, 3 year local control, locoregional control and disease free survival were seen in 62.8%, 42.8% and 42.1% of the study patients. Primary tumor site, nodal stage of disease, AJCC stage of the disease and number of cycles of weekly cisplatin demonstrated statistically significant correlations with 3 year local control, locoregional control and disease free survival. Conclusions: Concurrent chemoradiotherapy with moderate dose weekly cisplatin is an efficacious treatment regime for locally advanced head and neck cancers with tolerable toxicity which can be used in developing countries with limited resources.

Chemoradiation Related Acute Morbidity in Carcinoma Cervix and Correlation with Hematologic Toxicity: A South Indian Prospective Study

  • Kumaran, Aswathy;Guruvare, Shyamala;Sharan, Krishna;Rai, Lavanya;Hebbar, Shripad
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권11호
    • /
    • pp.4483-4486
    • /
    • 2014
  • Purpose: To assess chemoradiation related acute morbidity in women with carcinoma cervix and to find and correlation between hematologic toxicity and organ system specific damage. Materials and Methods: A prospective study was carried out between August 2012 and July 2013 enrolling 79 women with cancer cervix receiving chemo-radiotherapy. Weekly assessment of acute morbidity was done using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4 and the toxicities were graded. Results: Anemia [77 (97.5%)], vomiting [75 (94.8%)] and diarrhea [72 (91.1%)], leukopenia [11 (13.9%)], cystitis [28 (35.4%], dermatitis [19 (24.1%)] and fatigue [29 (36.71%)] were the acute toxicities noted. The toxicities were most severe in $3^{rd}$ and $5^{th}$ week. All women could complete radiotherapy except two due to causes unrelated to radiation morbidity; seven (8.86%) had to discontinue chemotherapy due to leukopenia and intractable diarrhea. Though there was no correlation between anemia and other toxicities, it was found that all with leukopenia had diarrhea. Conclusions: Chemoradiation for cancer cervix is on the whole well tolerated. Leukopenia and severe diarrhea were the acute toxicities that compelled discontinuation of chemotherapy in two women. Though anemia had no correlation with gastrointestinal toxicity, all of those with leukopenia had diarrhea.

한방치료와 화학·방사선요법을 병행하여 완전 관해된 진행성 위암 환자 1례 (A Case Report of Complete Response of Advanced Gastric Carcinoma Patient Treated with Korean Medicine Treatment in Conjunction with Chemoradiation Therapy)

  • 이재찬;윤호영;유화승;방선휘
    • 대한암한의학회지
    • /
    • 제19권1호
    • /
    • pp.25-32
    • /
    • 2014
  • Objectives : The purpose of this study is to report the effect of Korean Medicine Treatment (KMT) on the advanced gastric carcinoma (AGC) patient. Method : One advanced gastric carcinoma patient was treated by Korean Medicine Treatment composed of pharmacopuncture, acupuncture and herbal medicine. At the same time, he received chemotherapy (S-1 and Cisplatin) and radiotherapy. The effect of KMT was measured by scanning with Computed tomography (CT) and Esophagogastroduodenoscopy (EGD). Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Committee classification. Result : The tumor was disappeared after the treatment during 13 months (Complete Response (CR)). As treatment was performed, chemoradiation therapy induced complication was alleviated. Conclusion : This case provides us a possibility that Korean Medicine Treatment offers potential benefits for advanced gastric carcinoma patient.

Can Capecitabine be used Instead of Concurrent Bolus 5-FU in Postoperative Chemoradiotherapy for Gastric Adenocarcinoma?

  • Yoney, Adnan;Isikli, Levent
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권9호
    • /
    • pp.5127-5131
    • /
    • 2013
  • Background: 5-fluoro-uracil (FU) is a common agent in postoperative chemoradiation in gastric adenocarcinoma. However, FU is not well tolerated in a significant proportion of patients. Capecitabine (CA) is an orally administered fluoropyrimidine carbamate which is preferentially converted to active 5-FU and is one of the agents used instead of FU in such cases. We compared the toxicity, local and distant control and survival rates with FU or oral CA during the course of concurrent radiotherapy to assess the role of CA used instead of FU. Materials and Methods: We conducted an analysis of survival, disease control and toxicity data in 46 patients treated with postoperative chemoradiation following total or subtotal gastrectomy for gastric adenocarcinoma with either FU or CA between January 2008 and December 2012. Results: Median follow-up was 19 months (range: 3-59), median survival time was 23 ({\pm}6.08) months and 1-3 years overall survival (OS) rates were 64.9-39% for all patients. Compared with the CA regimen, the incidence of treatment interruption was higher with FU (p=0.023), but no significant differences were seen in local control (p=0.510), distant recurrences (p=0.721) and survival rates (p=0.866) among patients. Conclusions: Concurrent CA with radiotherapy seems to be a more tolerable and an equally effective regimen for the postoperative treatment of gastric adenocarcinoma when compared to FU.

Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand

  • Darunikorn, Pichayada;Puataweepong, Putipun;Dhanachai, Mantana;Dangprasert, Somjai;Swangsilpa, Thiti;Sitathanee, Chomporn;Jiarpinitnun, Chuleeporn;Pattaranutaporn, Poompis;Boonyawan, Keeratikan;Chansriwong, Pichai
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권16호
    • /
    • pp.7315-7319
    • /
    • 2015
  • Objectives: The study analyzed and compared the long term outcome in locally advanced rectal cancer treated with preoperative and postoperative concurrent chemoradiation (CCRT). Materials and Methods: A retrospective review of 105 patients with stage T3-T4 or regional lymph node positive adenocarcinoma of rectum treated with preoperative or postoperative CCRT at Ramathibodi Hospital during 2005 to 2010 was performed. The results of treatment were reported with 5-year overall survival (OS), 5-year locoregional recurrence free survival (LRFS), and toxicity according to preoperative versus postoperative concurrent chemoradiation (CCRT) groups. Results: Among 105 patients, 34 (32%) were treated with preoperative CCRT and 71 (68%) with postoperative CCRT. At the median follow-up time of 50.5 months (range 2-114 months), five-year OS and LRFS of all patients were 87% and 91.6%, respectively. The study found no difference in 5-year OS (81.7% vs 89.2 %) or LRFS (83.4% vs 95.1%) between preoperative versus postoperative CCRT. Seven cases of loco-regional recurrence were diagnosed, 4 (11.8%) after preoperative CCRT and 3 (4.2%) after postoperative CCRT. The recurrent sites were anastomosis in all patients. There was no significant factor associated with outcome after univariate and multivariate testing. Grade 3 or 4 acute and late complications were low in both preoperative and postoperative CCRT groups. Conclusions: Locally advanced rectum cancer patients experience good results with surgery and adjuvant concurrent chemoradiation.

화학방사선 요법이 치아발육에 미치는 영향에 관한 증례보고 (EFFECT OF CHEMORADIATION THERAPY ON THE DEVELOPING DENTITION : A CASE REPORT)

  • 김재곤;김영신;양정숙;이승영;백병주
    • 대한소아치과학회지
    • /
    • 제26권2호
    • /
    • pp.331-338
    • /
    • 1999
  • 하악 좌측부위의 횡문근육종으로 2년동안의 화학요법과 6주간의 방사선요법으로 치료를 받았고, 이에 따른 후유증으로 치아의 발육장애를 동반한 8세 환아에 대해, 임상적, 방사선학적으로 관찰을 시행하고, 치료한 결과 다음을 보고하는 바이다. 1. 구강내 소견으로서 맹출한 영구치의 경미한 법랑질 형성부전과 치아우식이 관찰되었으며, 하악 좌측 부위의 미맹출된 제 1 대구치로 인해 수직고경이 상실되어 과개교합이 형성되었다. 2. 방사선학적으로 맹출한 영구치의 치근은 짧은 치근에서부터 무형성증에 이르기까지 다양한 치근으 발육장애를 보였으며, 미맹출 상태인 제 2 소구치와 제 2 대구치는 왜소치나 형성부전의 소견을 보였다. 3. 치료는 보존치료 및 저석회화 소견을 보이는 영구치를 위해 불소도포를 시행하였고, 향후 적절한 수직고경의 회복과 심미적 개선을 위한 포괄적인 보철치료가 수행되어야 할 것으로 사료된다.

  • PDF